These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 32667213)

  • 61. Management of severe hidradenitis suppurativa with biologic therapy and wide excision.
    Lim SYD; Cheong EC; Oon HH
    Arch Plast Surg; 2019 May; 46(3):272-276. PubMed ID: 31006182
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study.
    Hafner A; Ghislain PD; Kovács R; Batchelor R; Katoulis AC; Kirby B; Banayan H; Schonbrun M
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):2277-2284. PubMed ID: 34320249
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunomodulatory drugs alone and adjuvant to surgery for hidradenitis suppurativa/acne inversa-A narrative review.
    Wollina U; Brzezinski P; Koch A; Philipp-Dormston WG
    Dermatol Ther; 2020 Nov; 33(6):e13877. PubMed ID: 32558202
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inflammasomes: emerging therapeutic targets in hidradenitis suppurativa?
    Campbell C; Mayatra JM; Neve AJ; Fletcher JM; Johnston DGW
    Br J Dermatol; 2024 Oct; 191(5):670-679. PubMed ID: 38913409
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effectiveness and Safety of Acitretin for the Treatment of Hidradenitis Suppurativa, Predictors of Clinical Response: A Cohort Study.
    Sánchez-Díaz M; Díaz-Calvillo P; Rodríguez-Pozo JÁ; Arias-Santiago S; Molina-Leyva A
    Dermatology; 2023; 239(1):52-59. PubMed ID: 35998603
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What's New?
    Ghanian S; Yamanaka-Takaichi M; Naik HB; Alavi A
    Am J Clin Dermatol; 2022 Mar; 23(2):167-176. PubMed ID: 34990004
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.
    Diamantova D; Lomickova I; Cetkovska P
    Acta Dermatovenerol Croat; 2014; 22(4):291-3. PubMed ID: 25580790
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Therapies for hidradenitis suppurativa: a systematic review with a focus on Brazil.
    Rivitti-Machado MC; Ferreira Magalhães R; Souto da Silva R; Duarte GV; Bosnich FZ; Tunala RG; Forestiero FJ
    Drugs Context; 2022; 11():. PubMed ID: 35145556
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
    Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
    Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review.
    Montero-Vilchez T; Pozo-Román T; Sánchez-Velicia L; Vega-Gutiérrez J; Arias-Santiago S; Molina-Leyva A
    J Dermatolog Treat; 2022 Feb; 33(1):348-353. PubMed ID: 32279593
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.
    Fotiadou C; Vakirlis E; Ioannides D
    Clin Cosmet Investig Dermatol; 2016; 9():367-372. PubMed ID: 27799806
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort.
    Argyropoulou M; Kanni T; Kyprianou M; Melachroinopoulos N; Giamarellos-Bourboulis EJ
    Br J Dermatol; 2019 May; 180(5):1161-1168. PubMed ID: 30192377
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Combination of oral zinc gluconate and topical triclosan: An anti-inflammatory treatment modality for initial hidradenitis suppurativa.
    Hessam S; Sand M; Meier NM; Gambichler T; Scholl L; Bechara FG
    J Dermatol Sci; 2016 Nov; 84(2):197-202. PubMed ID: 27554338
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Severe refractory hidradenitis suppurativa successfully treated with adalimumab in an HIV-positive/hepatitis C virus-positive patient.
    Molina-Leyva A; Badiola J
    AIDS; 2018 Oct; 32(16):2436-2438. PubMed ID: 30281563
    [No Abstract]   [Full Text] [Related]  

  • 75. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
    Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
    J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Staphylococcus aureus Carriage in Hidradenitis Suppurativa: Impact on Response to Adalimumab.
    Stergianou D; Tzanetakou V; Argyropoulou M; Kanni T; Bagos PG; Giamarellos-Bourboulis EJ
    Dermatology; 2021; 237(3):372-377. PubMed ID: 33401280
    [TBL] [Abstract][Full Text] [Related]  

  • 77. B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab.
    Hambly R; Gatault S; Smith CM; Iglesias-Martinez LF; Kearns S; Rea H; Marasigan V; Lynam-Loane K; Kirthi S; Hughes R; Fletcher JM; Kolch W; Kirby B
    Br J Dermatol; 2023 Jan; 188(1):52-63. PubMed ID: 36689500
    [TBL] [Abstract][Full Text] [Related]  

  • 78. An Update on Medical Treatment Options for Hidradenitis Suppurativa.
    Deckers IE; Prens EP
    Drugs; 2016 Feb; 76(2):215-29. PubMed ID: 26659474
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: A 52-week analysis of a postmarketing surveillance study in Japan.
    Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T
    J Dermatol; 2023 Aug; 50(8):1034-1044. PubMed ID: 37264993
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: A retrospective bicentric experience.
    Melgosa Ramos FJ; García Ruiz R; Mateu Puchades A; Alfageme Roldán F
    Dermatol Ther; 2022 Jul; 35(7):e15558. PubMed ID: 35510581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.